Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Sponsor: Kafrelsheikh University
Summary
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
Official title: Effect of Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
220
Start Date
2025-09-27
Completion Date
2026-02-01
Last Updated
2025-09-30
Healthy Volunteers
No
Interventions
Sacubitril/Valsartan
Patients will be treated with conventional anti-heart failure therapy plus sacubitril/valsartan (oral administration of an initial dose of 24/26 mg twice daily, gradually increasing to 97/103 mg, depending on follow-up blood pressure) \[Entresto, 100 mg (sacubitril 49 mg/valsartan 51 mg)\].
Conventional anti-heart failure therapy
Patients will be treated only with conventional anti-heart failure therapy as a control group.
Locations (1)
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt